Hormonal
Roux-en-Y gastric bypass (RYGB) surgery increases glycemic variability and time in hypoglycemic ranges in both diabetic and non-diabetic patients within six months post-operation, with non-diabetic patients showing a significant decrease in time in range due to increased hypoglycemia.
If you undergo Roux-en-Y gastric bypass, expect your blood sugar to fluctuate more, including episodes of low blood sugar (hypoglycemia), even if you did not have diabetes before. This happens because the surgery speeds up how food enters your intestine. Use a continuous glucose monitor to track these changes, as standard HbA1c tests might miss these dangerous lows.
The CGM identified an increase in time below range in both groups undergoing RYGB after six months when compared to the preoperative period... In this same group [without T2DM], there was a significant decrease in TIR due to the increase in time in hypoglycemia. Such findings suggest a higher GV in patients with T2DM undergoing RYGB and even in patients without a diagnosis of T2DM before surgery.
Why this rating
Small sample size (14 operated patients + 7 controls) and short follow-up (6 months), though using continuous glucose monitoring.
Source
Avaliação da variabilidade glicêmica em pacientes submetidos à derivação gástrica em Y de Roux com ou sem diabete melito tipo 2
Raquel do Amaral Prado Quevedo · 2024
DOI 10.11606/d.5.2024.tde-02072024-161545
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →